Inhaled Technosphere Insulin Compared With Injected Prandial Insulin in Type 1 Diabetes: A Randomized 24-Week Trial
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To compare the efficacy and safety of Technosphere insulin (TI) and insulin aspart in patients with type 1 diabetes. RESEARCH DESIGN AND METHODS: This open-label noninferiority trial compared the change in HbA1c from baseline to week 24 of prandial TI (n = 174) with that of subcutaneous aspart (n = 171), both with basal insulin, in patients with type 1 diabetes and HbA1c 7.5–10.0% (56.8–86.0 mmol/mol). RESULTS: Mean change in HbA1c in TI patients (–0.21% [–2.3 mmol/mol]) from baseline (7.94% [63.3 mmol/mol]) was noninferior to that in aspart patients (–0.40% [–4.4 mmol/mol]) from baseline (7.92% [63.1 mmol/mol]). The between-group difference was 0.19% (2.1 mmol/mol) (95% CI 0.02–0.36), satisfying the noninferiority margin of 0.4%. However, more aspart patients achieved HbA1c <7.0% (53.0 mmol/mol) (30.7% vs. 18.3%). TI patients had a small weight loss (–0.4 kg) compared with a gain (+0.9 kg) for aspart patients (P = 0.0102). TI patients had a lower hypoglycemia event rate than aspart patients (9.8 vs. 14.0 events/patient-month, P < 0.0001). Cough (generally mild) was the most frequent adverse event (31.6% with TI, 2.3% with aspart), leading to discontinuation in 5.7% of patients. Treatment group difference for mean change from baseline in forced expiratory volume in 1 s was small (40 mL) and disappeared upon TI discontinuation. CONCLUSIONS: In patients with type 1 diabetes receiving basal insulin, HbA1c reduction with TI was noninferior to that of aspart, with less hypoglycemia and less weight gain but increased incidence of cough.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the use of rapid-acting analogs has resulted in less hypoglycemia, with small reductions in A1C compared to using regular human insulin, including MDI using NPH as basal insulin.1151–1153”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1153]
In the citing paper
“Results from comparative effectiveness meta-analyses suggest that each new class of oral noninsulin agents when added to metformin generally lowers A1C by approximately 0.7-1.0%(8-11 mmol/mol).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [10]
Citations
Cites
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Spirometric Reference Values from a Sample of the General U.S. Population
HANKINSON, J. L., ODENCRANTZ, J. R., & FEDAN, K. B. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.159.1.9712108 · Cited by 4,206 · cited 1×
“criteria were nonsmoking for the preceding 6 months, BMI #38 kg/m(2), forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) $70% predicted (11), and stable insulin dose (,2 IU/kg/day) with fasting plasma glucose (FPG),220mg/dL for 3months before screening.”
BackgroundThe prevention and treatment of missing data in clinical trials
Little, R. J., D'Agostino, R., Cohen, M. L., Dickersin, K., Emerson, S. S., Farrar, J. T., Frangakis, C., Hogan, J. W., Molenberghs, G., Murphy, S. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmsr1203730 · Cited by 1,884
Morris, A. D., Boyle, D. I., McMahon, A. D., Greene, S. A., MacDonald, T. M., & Newton, R. W. (1997) · The Lancet · doi:10.1016/s0140-6736(97)06234-x · Cited by 507
Correlates of Insulin Injection Omission
Peyrot, M., Rubin, R. R., Kruger, D. F., & Travis, L. B. (2010) · Diabetes Care · doi:10.2337/dc09-1348 · Cited by 407 · cited 1×
“Lack of compliance with insulin therapy is a frequent problem in patients with type 1 diabetes due to pain and embarrassment associated with insulin injections (5).”
BackgroundGlycemic Exposure Is Associated With Reduced Pulmonary Function in Type 2 Diabetes
Davis, W. A., Knuiman, M., Kendall, P., Grange, V., & Davis, T. M. E. (2004) · Diabetes Care · doi:10.2337/diacare.27.3.752 · Cited by 323 · cited 1×
“There is some evidence that the decline in pulmonary function in patients with diabetes is greater than that of the general population (22).”
BackgroundMMRM vs. LOCF: A Comprehensive Comparison Based on Simulation Study and 25 NDA Datasets
Siddiqui, O., Hung, H. M. J., & O'Neill, R. (2009) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543400802609797 · Cited by 301 · cited 1×
“First, the analysis method (MMRM) is a preferred model for addressing missing data (23,24).”
MethodUse of Inhaled Insulin in a Basal/Bolus Insulin Regimen in Type 1 Diabetic Subjects
Skyler, J. S., Weinstock, R. S., Raskin, P., Yale, J.-F., Barrett, E., Gerich, J. E., Gerstein, H. C., & the Inhaled Insulin Phase III Type 1 Diabetes Study Group (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1630 · Cited by 269
Hypoglycemia in Type 1 Diabetes Mellitus
Cryer, P. E. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.05.003 · Cited by 205
Rosenstock, J., Lorber, D. L., Gnudi, L., Howard, C. P., Bilheimer, D. W., Chang, P.-C., Petrucci, R., Boss, A., & Richardson, P. C. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60632-0 · Cited by 122
Self-citationBosi, E., Scavini, M., Ceriello, A., Cucinotta, D., Tiengo, A., Marino, R., Bonizzoni, E., Giorgino, F., & on behalf of the PRISMA Study Group (2013) · Diabetes Care · doi:10.2337/dc13-0092 · Cited by 105
Ciofetta, M., Lalli, C., Del Sindaco, P., Torlone, E., Pampanelli, S., Mauro, L., Chiara, D. L., Brunetti, P., & Bolli, G. B. (1999) · Diabetes Care · doi:10.2337/diacare.22.5.795 · Cited by 99
Sindaco, P. D., Ciofetta, M., Lalli, C., Perriello, G., Pampanelli, S., Torlone, E., Brunetti, P., & Bolli, G. B. (1998) · Diabetic Medicine · doi:10.1002/(sici)1096-9136(199807)15:7<592::aid-dia625>3.0.co;2-j · Cited by 96
Tamás, G., Marre, M., Astorga, R., Dedov, I. I., Jacobsen, J. B., & Olinder, A. L. (2001) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(01)00262-5 · Cited by 78
Technosphere ® Insulin Technology
Richardson, P. C., & Boss, A. (2007) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2007.0212 · Cited by 75 · cited 1×
“maximum serum insulin concentration of ;12–15 min (8,9).”
BackgroundCoverage of Prandial Insulin Requirements by Means of an Ultra-Rapid-Acting Inhaled Insulin
Boss, A. H., Petrucci, R., & Lorber, D. (2012) · Journal of Diabetes Science and Technology · doi:10.1177/193229681200600406 · Cited by 67
Self-citationA Review of Inhaled Technosphere Insulin
Neumiller, J. J., Campbell, R. K., & Wood, L. D. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1p055 · Cited by 60 · cited 1×
“consistent with data collected throughout the TI development program describing the pulmonary tolerability and safety of TI (12).”
MethodRave, K., Heise, T., Heinemann, L., & Boss, A. H. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200206 · Cited by 57
Peyrot, M., Skovlund, S. E., & Landgraf, R. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903073654 · Cited by 48 · cited 1×
“weight gain also contribute to reduced adherence (6).”
BackgroundPharmacokinetic Characterization of the Novel Pulmonary Delivery Excipient Fumaryl Diketopiperazine
Potocka, E., Cassidy, J. P., Haworth, P., Heuman, D., van Marle, S., & Baughman, R. A. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400515 · Cited by 48 · cited 1×
“FDKP is excreted unchanged in the urine (10).”
BackgroundLimitations of the so-called “intensified” insulin therapy in type 1 diabetes mellitus
Jacqueminet, S., Massebœuf, N., Rolland, M., Grimaldi, A., & Sachon, C. (2005) · Diabetes & Metabolism · doi:10.1016/s1262-3636(05)88267-9 · Cited by 29 · cited 1×
“(3), whereas severe hypoglycemia can be life threatening (4).”
BackgroundInsulin detemir for the treatment of obese patients with type 2 diabetes
Hollander, P. A. (2012) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s26980 · Cited by 19
Insulin Antibodies with Pulmonary Delivery of Insulin
Fineberg, S. E., Kawabata, T. T., Krasner, A. S., & Fineberg, N. S. (2007) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2007.0207 · Cited by 16 · cited 1×
“probably associated with the lungs’ immunological properties (25).”
BackgroundLeone‐Bay, A., & GRANT, M. L. (2008) · CRC Press eBooks · doi:10.3109/9781420045260-51 · Cited by 15
Edgerton, D. S., Cherrington, A. D., Neal, D. W., Scott, M. F., Lautz, M., Brown, N. J., Petro, J., HOBBS, C. H., Leach, C., Parigi, A. D., et al. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.146985 · Cited by 6 · cited 1×
“be due to better peripheral glucose utilization after delivery of inhaled insulin (18).”
Background
Cited by
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s009 · Cited by 972
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s009 · Cited by 914
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s009 · Cited by 851
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s009 · Cited by 739
Metadata
- Authors
- Bode, B. W., McGill, J. B., Lorber, D. L., Gross, J. L., Chang, P.-C., Bregman, D. B., & for the Affinity 1 Study Group
- Affiliations
- Atlanta Diabetes Associates (US)
- Washington University in St. Louis (US)
- NewYork–Presbyterian Hospital (US)
- Centro de Pesquisas em Diabetes Ltda., Porto Alegre, Brazil
- MannKind Corporation (United States) (US)
- Albert Einstein College of Medicine (US)
- Corresponding author
- Bode, Bruce W.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-07-15
- Volume
- 38
- Issue
- 12
- Pages
- 2266-2273
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2102067048
- Cited by
- 114
- References
- 24
- Citations by year
- 2026: 19 · 2025: 11 · 2024: 7 · 2023: 9 · 2022: 9 · 2021: 9 · 2020: 15 · 2019: 5 · 2018: 11 · 2017: 7 · 2016: 10 · 2015: 2
- FWCI
- 8.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- MannKind Corporation
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- Technosphere insulin, inhaled insulin, insulin aspart, type 1 diabetes, prandial insulin, basal insulin, glycemic control, HbA1c, hypoglycemia, weight gain, cough, non-inferiority
- MeSH terms
- Administration, Inhalation, Adolescent, Adult, Aged, Diabetes Mellitus, Type 1, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Microspheres, Middle Aged, Powders, Young Adult, Insulin Aspart, Insulin, Regular, Human
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.